Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lynch Syndrome
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
By
Wayne Kuznar
Lynch Syndrome
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Based on results of a study presented at ASCO 2018, the presence of an MSI-H or dMMR tumor signature, regardless of cancer type or family history, should prompt genetic testing to evaluate for Lynch syndrome.
Read Article
Top Trending Articles
1.
HOPA Highlights: What's New in 2025?
2.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma